Biomerica, a developer of point-of-care diagnostic products, has launched new E coli tests.
The test including E coli O157 is used for the determination of E coli 0157 and Verotoxin is used to detect both verotoxin 1 and verotoxin 2 (VT1 and VT2).
The clinical importance of the new assays in the diagnosis and treatment of patients with diarrheal disease is evidenced by the Centers for Disease Control and Prevention (CDC) recommendations.
The recommendations includes that all cases of acute community-acquired diarrhea should be simultaneously cultured for E coli O157:H7 and tested with an assay that detects verotoxins (Shiga toxins) to diagnose non-O157 Shiga toxin-producing E coli (STEC).
Biomerica CEO Zackary Irani said the company has achieved the first step towards entering the foodborn and infectious disease markets, and it will be expanding the test menu for these markets.